Abstract:

Objective To investigate the autologous cytokine-induced killer（CIK） cells on the immunity function of cancer patients in different stages. Methods One hundred and sixty-two malignant tumor patients were divided into 3 groups， terminalstage patients and the expected survival time less than 3 months were the group A， the patients who existed distant metastases or locally advanced cancer and the expected survival time longer than 3 months were the group B， and the cases who finished postoperative adjuvantherapy were the group C， meanwhile the health volunteers were as the group D. We detected immunity function of the patients，including the levels of CD3+, CD3+CD4+, CD3+CD8+, CD3+CD56+T cells and the ratio of CD4+／CD8+，meanwhile the adverse reactions were monitored. Results Before the CIK cells therapy， the baseline level of CD3+， CD3+CD4+，CD3+CD8+T cell subsets and the ratio of CD4+／CD8+ among the groups were statistically significant differences（P＜0.05）. After twice CIK cells therapy， the level of CD3+T cells decreased in group A（P＜0.05）; and compared with group D， the levels of CD3+， CD3+CD4+， CD3+CD8+， CD3+CD56+ and CD4+／CD8+were still significantly different（P＜0.05）. The levels of CD3+， CD3+CD56+T lymphocytes increased（P＜0.05） in group B， CD3+，CD3+CD4+ and CD3+CD8+ were still significantly different（P＜0.05）. The levels of CD3+， CD3+CD4+， CD3+CD56+T cell subsets also increased（P＜0.05）in group C， and CD3+， CD3+CD4+， CD3+CD8+， CD3+CD56+ and CD4+／CD8+ were not significantly different compared with group D. The adverse reaction among each groups were in a low rate during treatment and had no statistical significance. Conclusion The autologous CIK cells treatment may help to improve T-lymphocyte subsets distribution and improve the host's immune functions. Meanwhile the adverse reactions in the process of treatment can be alleviated by heteropathy and has no relationship with the status of tumor.